Skip to main content

Table 3 KEGG pathway enrichment

From: Vascular endothelial growth factor A as predictive marker for mTOR inhibition in relapsing high-grade serous ovarian cancer

Pathway

# Genes

Estimate

p-value

hsa04350:TGF-beta signaling pathway

11

11.58

1.00E-05

hsa03010:Ribosome

11

11.58

1.00E-05

hsa04150:mTOR signaling pathway

8

8.42

1.04E-04

hsa02010:ABC transporters

7

7.37

3.36E-04

hsa04630:Jak-STAT signaling pathway

9

9.47

0.00901

hsa04620:Toll-like receptor signaling pathway

7

7.37

0.01620

hsa04010:MAPK signaling pathway

11

11.58

0.01982

hsa04914:Progesterone-mediated oocyte maturation

6

6.32

0.03358

hsa04012:ErbB signaling pathway

6

6.32

0.03330

hsa04722:Neurotrophin signaling pathway

7

7.37

0.03265

hsa04060:Cytokine-cytokine receptor interaction

10

10.53

0.04148

  1. Pathways according to KEGG computed as significantly enriched in molecular process 4 of the HGSOCr molecular model. Pathways given in bold are further identified as enriched in the drug mechanism of action model overlap feature set of cisplatin and paclitaxel matching with molecular process 4 members of the HGSOCr molecular model
Back to article page

BMC Systems Biology

ISSN: 1752-0509

Contact us